MARIMED INC. 10-Q

Item 1. Financial Statements MariMed Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) (unaudited) March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 21,595 $ 9,737 Accounts receivable, net of allowances of $ 716 and $ 4,603 at March 31, 2023 and December 31, 2022, respectively 4,334 4,157 Deferred rents receivable 686 704 Notes receivable, current portion 2,639 2,637 Inventory 22,723 19,477 Investments, current 104 123 Due from related parties 49 29 Other current assets 7,244 7,282 Total current assets 59,374 44,146 Property and equipment, net 73,714 71,641 Intangible assets, net 19,480 14,201 Goodwill 12,004 8,079 Notes receivable, net of current 7,523 7,467 Operating lease right-of-use assets 10,122 4,931 Finance lease right-of-use assets 871 713 Other assets 1,303 1,024 Total assets $ 184,391 $ 152,202 Liabilities, mezzanine equity and stockholders’ equity Current liabilities: Term loan $ 3,300 $ — Mortgages and notes payable, current portion 2,773 3,774 Accounts payable 4,665 6,626 Accrued expenses and other 2,968 3,091 Income taxes payable 8,683 11,489 Operating lease liabilities, current portion 1,798 1,273 Finance lease liabilities, current portion 322 237 Total current liabilities 24,509 26,490 Term loan, net of current 20,803 — Mortgages and notes payable, net of current 26,610 25,943 Operating lease liabilities, net of current 8,837 4,173 Finance lease liabilities, net of current 538 461 4 Table of Contents MariMed Inc. Condensed Consolidated Balance Sheets (continued) (in thousands, except share and per share amounts) (unaudited) March 31, 2023 December 31, 2022 Other liabilities 100 100 Total liabilities 81,397 57,167 Commitments and contingencies Mezzanine equity: Series B convertible preferred stock, $ 0.001 par value; 4,908,333 shares authorized, issued and outstanding at March 31, 2023 and December 31, 2022 14,725 14,725 Series C convertible preferred stock $ 0.001 par value; 12,432,432 shares authorized; 6,216,216 shares issued and outstanding at March 31, 2023 and December 31, 2022 23,000 23,000 Total mezzanine equity 37,725 37,725 Stockholders’ equity Undesignated preferred stock, $ 0.001 par value; 32,659,235 shares authorized; zero shares issued and outstanding at March 31, 2023 and December 31, 2022 — — Common stock, $ 0.001 par value; 700,000,000 shares authorized; 348,126,911 and 341,474,728 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 348 341 Common stock subscribed but not issued 2 39 Additional paid-in capital 151,052 142,365 Accumulated deficit ( 84,569 ) ( 83,924 ) Noncontrolling interests ( 1,564 ) ( 1,511 ) Total stockholders’ equity 65,269 57,310 Total liabilities, mezzanine equity and stockholders’ equity $ 184,391 $ 152,202 See accompanying notes to the unaudited condensed consolidated financial statements. 5 Table of Contents MariMed Inc. Condensed Consolidated Statements of Operations (in thousands, except per share amounts) (unaudited) Three months ended March 31, 2023 2022 Revenue $ 34,380 $ 31,282 Cost of revenue 18,992 14,306 Gross profit 15,388 16,976 Operating expenses: Personnel 4,656 3,042 Marketing and promotion 1,146 643 General and administrative 4,305 6,228 Acquisition-related and other 190 — Bad debt ( 44 ) 14 Total operating expenses 10,253 9,927 Income from operations 5,135 7,049 Interest and other (expense) income: Interest expense ( 2,505 ) ( 313 ) Interest income 99 163 Other (expense) income, net ( 900 ) 1,002 Total interest and other (expense) income ( 3,306 ) 852 Income before income taxes 1,829 7,901 Provision for income taxes 2,493 3,660 Net (loss) income ( 664 ) 4,241 Less: Net (loss) income attributable to noncontrolling interests ( 19 ) 53 Net (loss) income attributable to common stockholders $ ( 645 ) $ 4,188 Net (loss) earnings per share attributable to common stockholders: Basic $ ( 0.00 ) $ 0.01 Diluted $ ( 0.00 ) $ 0.01 Weighted average common shares outstanding: Basic 342,794 334,763 Diluted 342,794 378,890 See accompanying notes to the unaudited condensed consolidated financial statements. 6 Table of Contents MariMed Inc. Condensed Consolidated Statements of Stockholders’ Equity (in thousands, except share amounts) (unaudited) Three months ended March 31, 2023 Common stock Common stock subscribed but not issued Additional paid-in capital Accumulated deficit Non- controlling interests Total stockholders’ equity Shares Par value Shares Amount Balances at January 1, 2023 341,474,728 $ 341 70,000 $ 39 $ 142,365 $ ( 83,924 ) $ ( 1,511 ) $ 57,310 Issuance of subscribed shares 70,000 — ( 70,000 ) ( 39 ) 39 — — — Common stock subscribed but not issued — — 5,025 2 — — — 2 Warrants issued in connection with debt — — — — 5,454 — — 5,454 Shares issued as purchase consideration - business acquisition 6,580,390 7 — — 2,987 — — 2,994 Common stock issued to settle obligations 1,793 — — — 1 — — 1 Distributions to non-controlling interests 0 — — — — — ( 34 ) ( 34 ) Stock-based compensation 0 — — — 206 — — 206 Net loss 0 — — — — ( 645 ) ( 19 ) ( 664 ) Balances at March 31, 2023 348,126,911 $ 348 5,025 $ 2 $ 151,052 $ ( 84,569 ) $ ( 1,564 ) $ 65,269 Three months ended March 31, 2022 Common stock Common stock subscribed but not issued Additional paid-in capital Accumulated deficit Non- controlling interests Total stockholders’ equity Shares Par value Shares Amount Balances at January 1, 2022 334,030,348 $ 334 — $ — $ 134,920 $ ( 97,392 ) $ ( 1,563 ) $ 36,299 Exercise of stock options 10,000 — — — 3 — — 3 Common stock subscribed but not issued — — 2,717 2 — — — 2 Conversion of promissory notes to equity 1,142,858 1 — — 399 — — 400 Obligations settled with common stock 375,000 1 — — 273 — — 274 Distributions to non-controlling interests — — — — — — ( 101 ) ( 101 ) Stock-based compensation — — — — 2,469 — — 2,469 Net income — — — — — 4,188 53 4,241 Balances at March 31, 2022 335,558,206 $ 336 2,717 $ 2 $ 138,064 $ ( 93,204 ) $ ( 1,611 ) $ 43,587 See accompanying notes to the unaudited condensed consolidated financial statements. 7 Table of Contents MariMed Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) Three months ended March 31, 2023 2022 Cash flows from operating activities: Net (loss) income attributable to common stockholders $ ( 645 ) $ 4,188 Net (loss) income attributable to noncontrolling interests ( 19 ) 53 Adjustments to reconcile net (loss) income to cash (used in) provided by operating activities: Depreciation and amortization of property and equipment 986 702 Amortization of intangible assets 557 140 Stock-based compensation 208 2,471 Amortization of original issue discount 55 — Amortization of debt discount 328 — Payment-in-kind interest 118 — Present value adjustment of notes payable 719 — Bad debt (income) expense ( 44 ) 14 Obligations settled with common stock 1 274 Write-off of disposed assets 906 — Gain on finance lease adjustment ( 13 ) — Loss (gain) on changes in fair value of investments 20 ( 48 ) Other investment income — ( 954 ) Changes in operating assets and liabilities: Accounts receivable, net ( 132 ) ( 1,810 ) Deferred rents receivable 18 92 Inventory ( 3,246 ) ( 2,470 ) Other current assets 639 ( 739 ) Other assets 19 — Accounts payable ( 1,961 ) 3,212 Accrued expenses and other ( 207 ) ( 227 ) Income taxes payable ( 2,806 ) 3,592 Net cash (used in) provided by operating activities ( 4,499 ) 8,490 Cash flows from investing activities: Purchases of property and equipment ( 3,052 ) ( 4,015 ) Business acquisitions, net of cash acquired ( 2,995 ) — 8 Table of Contents MariMed Inc. Condensed Consolidated Statements of Cash Flows (continued) (in thousands) (unaudited) Three months ended March 31, 2023 2022 Advances toward future business acquisitions ( 300 ) ( 100 ) Purchases of cannabis licenses ( 601 ) ( 305 ) Proceeds from notes receivable 43 43 Due from related party ( 20 ) — Net cash used in investing activities ( 6,925 ) ( 4,377 ) Cash flows from financing activities: Proceeds from issuance of term loan 29,100 — Principal payments of mortgages and promissory notes ( 212 ) ( 176 ) Repayment of promissory notes ( 5,503 ) — Proceeds from exercise of stock options — 3 Principal payments of finance leases ( 69 ) ( 55 ) Distributions ( 34 ) ( 101 ) Net cash provided by (used in) financing activities 23,282 ( 329 ) Net increase in cash and cash equivalents 11,858 3,784 Cash and equivalents, beginning of year 9,737 29,683 Cash and cash equivalents, end of period $ 21,595 $ 33,467 Supplemental disclosure of cash flow information: Cash paid for interest $ 1,100 $ 302 Cash paid for income taxes $ 5,296 $ 68 Non-cash activities: Common stock issued as purchase consideration $ 2,994 $ — Conversion of promissory notes to equity $ — $ 400 Present value of promissory note issued as purchase consideration $ 4,569 $ — Warrants to purchase common stock issued with debt $ 5,454 $ — Note payable issued to purchase motor vehicle $ 49 $ — Entry into new operating leases $ 5,366 $ — Entry into new finance leases $ 224 $ 514 Issuance of common stock associated with subscriptions $ 39 $ — See accompanying notes to the unaudited condensed consolidated financial statements. 9 Table of Contents MariMed Inc. Notes to Condensed Consolidated Financial Statements (unaudited) (1) BASIS OF PRESENTATION Business MariMed Inc. (“MariMed” or the “Company”) is a multi-state operator in the United States cannabis industry. MariMed develops, operates, manages and optimizes state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult use cannabis. MariMed also licenses its proprietary brands of cannabis, along with other top brands, in domestic markets. Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in accordance with accounting principles generally accepted in the United States of America (“GAAP”). On April 27, 2022 (the “Kind Acquisition Date”), the Company acquired Kind Therapeutics USA (“Kind”), the Company's former client in Maryland that holds licenses for the cultivation, production and dispensing of medical cannabis (the "Kind Acquisition"). The financial results of Kind are included in the Company’s condensed consolidated financial statements for the three months ended March 31, 2023. On March 9, 2023, (the "Ermont Acquisition Date"), the Company acquired the operating assets of Ermont, Inc. ("Ermont"), a medical-licensed vertical cannabis operator located in Quincy, Massachusetts (the "Ermont Acquisition"). The financial results of Ermont are included in the Company's condensed consolidated financial statements for the period subsequent to the Ermont Acquisition Date. The Company completed two acquisitions during the year ended December 31, 2022 that it recorded as asset purchases. On May 5, 2022 (the "Green Growth Acquisition Date"), the Company completed the acquisition of 100 % of the equity of Green Growth Group Inc. ("Green Growth"), an entity that holds a craft cultivation and production cannabis license in Illinois (the "Green Growth Acquisition"). On December 30, 2022 (the "Greenhouse Naturals Acquisition Date"), the Company completed an asset purchase under which it acquired a cannabis license and assumed a property lease for a dispensary in Beverly, Massachusetts that had never been operational. Interim results are not necessarily indicative of results for the full fiscal year or any future interim period. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “Annual Report”), which was filed with the U.S. Securities and Exchange Commission (“SEC”) on March 3, 2023. Significant Accounting Policies The Company’s significant accounting policies are disclosed in Note 2 to the Consolidated Financial Statements in the Annual Report. There were no material changes to the Company's significant accounting policies during the three-month period ended March 31, 2023. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of MariMed and its wholly- and majority-owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Noncontrolling interests represent third-party minority ownership interests in the Company’s majority-owned consolidated subsidiaries. Net income attributable to noncontrolling interests is reported in the condensed consolidated statements of operations, and the value of minority-owned interests is presented as a component of equity within the condensed consolidated balance sheets. 10 Table of Contents Use of Estimates and Judgments The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reporting amounts of revenue and expenses during the reporting periods. Significant estimates and judgments relied upon in preparing these condensed consolidated financial statements include accounting for business combinations and asset purchases, inventory valuations, assumptions used to determine the fair value of stock-based compensation, and intangible assets and goodwill. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values. At December 31, 2022, the Company had $ 0.1 million of cash held in escrow. The Company did no t have any cash held in escrow at March 31, 2023. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments approximate their fair values and include cash equivalents, accounts receivable, deferred rents receivable, notes receivable, term loans, mortgages and notes payable, and accounts payable. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The three-tier fair value hierarchy is based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is as follows: • Level 1 . Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. • Level 2 . Level 2 applies to assets or liabilities for which there are inputs that are directly or indirectly observable in the marketplace, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets). • Level 3 . Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, Accounting Standards Updates (“ASUs”) and does not believe that the future adoption of any such ASUs will have a material impact on its financial condition or results of operations. (2) BUSINESS COMBINATIONS AND ASSET PURCHASES Business Combinations Ermont On February 21, 2023, the Company announced its intention to acquire the operating assets of Ermont, Inc. ("Ermont"), a medical licensed vertical cannabis operator, located in Quincy, Massachusetts, subject to approval by the Massachusetts Cannabis Control Commission (the "CCC"). In March 2023, the CCC approved the Company's acquisition of Ermont, and the Ermont Acquisition was completed on the Ermont Acquisition Date. The Ermont Acquisition provided the Company 11 Table of Contents with its third dispensary in Massachusetts, substantially completing its build-out to the maximum allowable by state regulations. As consideration for the Ermont Acquisition, which totaled $ 13.0 million, the Company paid $ 3.0 million of cash, issued 6,580,390 shares of the Company's common stock, and issued a $ 7.0 million promissory note (the "Ermont Note", and collectively, the "Ermont Consideration"). The Ermont Note has a six-year term and bears interest at 6.0 % per annum, with payments of interest-only for two years and thereafter, quarterly payments of principal and interest in arrears. The outstanding balance on the Ermont Note is due and payable in full if and when the Company raises $ 75 million of equity capital. The Company rebranded the dispensary as Panacea Wellness Dispensary and commenced medical sales immediately after the Ermont Acquisition Date. The Ermont Acquisition includes a Host Community Agreement with the city of Quincy to conduct adult-use cannabis sales. The Company expects to commence adult-use sales upon approval by the CCC. The Company also plans to expand the existing medical dispensary to accommodate the expected increased traffic associated with adult-use sales. Additionally, the Company plans to repurpose Ermont's existing cultivation facility to use for its pheno-hunting activities. The Company expects this will allow it to move pheno-hunting out of its New Bedford facility and to use the freed space in New Bedford for much-needed additional capacity to cultivate its Nature's Heritage flower. The Company's condensed consolidated statement of operations for the three months ended March 31, 2023 includes approximately $ 230,000 of revenue and approximately $ 42,000 of net loss attributable to Ermont for the period since the Ermont Acquisition Date. The Ermont Acquisition has been accounted for as a business acquisition, and the financial results of Ermont have been included in the Company' condensed consolidated statements for the period since the Ermont Acquisition Date. The Company did not assume any of Ermont's liabilities. A summary of the preliminary of allocation of the Ermont Consideration to the acquired and identifiable intangible assets is as follows (in thousands): Fair value of consideration transferred: Cash consideration: Cash paid $ 3,000 Less cash acquired ( 5 ) Net cash consideration 2,995 Common stock 2,994 Promissory note 4,569 Total fair value of consideration $ 10,558 Fair value of assets acquired and (liabilities assumed): Property and equipment $ 800 Intangible assets: Tradename and trademarks 1,060 Licenses and customer base 4,773 Goodwill 3,925 Fair value of net assets acquired $ 10,558 The Company is amortizing the identifiable intangible assets arising from the Ermont Acquisition in relation to the expected cash flows from the individual intangible assets over their respective useful lives, which have a weighted average life of 10.91 years (see Note 9). Goodwill results from assets not separately identifiable as part of the transaction, and is not deductible for tax purposes. Kind In December 2021, the Company entered into a membership interest purchase agreement with the members of Kind to acquire 100 % of the equity ownership of Kind in exchange for $ 13.5 million payable in cash (subject to certain adjustments) and $ 6.5 million payable by the issuance of four-year 6.0 % promissory notes to the members of Kind, secured by a first priority lien on the Company’s property in Hagerstown, Maryland (collectively, the “Kind Consideration”). Kind was the Company's client in Maryland that held licenses for the cultivation, production and dispensing of medical cannabis. 12 Table of Contents Upon execution of the membership interest purchase agreement, the Company deposited $ 5.0 million into escrow as a contract down payment. In April 2022, the Maryland Medical Cannabis Commission approved the Company’s acquisition of Kind, and the Kind Acquisition was completed on the Kind Acquisition Date. Following the Kind Acquisition, litigation between the Company and the members of Kind was dismissed (see Note 18). The Kind Acquisition has been accounted for as a business combination, and the financial results of Kind have been included in the Company’s condensed consolidated financial statements since the Kind Acquisition Date. A summary of the final allocation of the Kind Consideration to the acquired assets, identifiable intangible assets and certain assumed liabilities is as follows (in thousands): Fair value of consideration transferred: Cash consideration: Cash paid at closing $ 10,128 Release of escrow 2,444 Severance paid from escrow 556 Less cash acquired ( 2,310 ) Net cash consideration 10,818 Note payable 5,634 Write-off accounts receivable 658 Write-off of deferred accounts receivable 842 Total fair value of consideration transferred $ 17,952 Fair value of assets acquired and (liabilities assumed): Current assets, net of cash acquired $ 5,047 Property and equipment 622 Intangible assets: Tradename and trademarks 2,041 Licenses and customer base 4,700 Non-compete agreements 42 Goodwill 6,011 Current liabilities ( 511 ) Fair value of net assets acquired $ 17,952 The Company is amortizing the identifiable intangible assets arising from the Kind Acquisition in relation to the expected cash flows from the individual intangible assets over their respective useful lives, which have a weighted average life of 5.77 years (see Note 9). Goodwill results from assets not separately identifiable as part of the transaction, and is not deductible for tax purposes. Concurrent with entering into the Kind membership purchase agreement, the Company entered into a membership interest purchase agreement with one of the members of Kind to acquire such member’s entire equity ownership interest in (i) Mari Holdings MD LLC (“Mari-MD”), the Company’s majority-owned subsidiary that owns production and retail cannabis facilities in Hagerstown, Maryland and Annapolis, Maryland, and (ii) Mia Development LLC (“Mia”), the Company’s majority-owned subsidiary that owns production and retail cannabis facilities in Wilmington, Delaware. Upon the dismissal in September 2022 of the derivative claims in the DiPietro lawsuit (see Note 18), the Company paid the aggregate purchase consideration of $ 2.0 million, and the transaction was completed, increasing the Company’s ownership of Mari-MD and Mia to 99.7 % and 94.3 %, respectively. The following unaudited pro forma information presents the condensed combined results of MariMed and Kind for the year ended December 31, 2022 as if the Kind Acquisition had been completed on January 1, 2021, with adjustments to give effect to pro forma events that are directly attributable to the Kind Acquisition. These pro forma adjustments include the reversal of MariMed revenue and related cost of sales derived from Kind prior to the Kind Acquisition Date, amortization expense for the acquired intangible assets, depreciation expense for property and equipment acquired by MariMed as part of the Kind Acquisition, and interest expense related to the Kind Notes. Pro forma adjustments also include the elimination 13 Table of Contents of acquisition-related and other expense directly attributable to the Kind Acquisition from the year ended December 31, 2022. The unaudited pro forma results do not reflect any operating efficiencies or potential cost savings that may result from the consolidation of the operations of MariMed and Kind. Accordingly, these unaudited pro forma results are presented for illustrative purposes and are not intended to represent or be indicative of the actual results of operations of the combined company that would have been achieved had the Kind Acquisition occurred at January 1, 2022, nor are they intended to represent or be indicative of future results of operations. The pro forma financial results for the year ended December 31, 2022 giving effect to the Kind Acquisition as if it had occurred at January 1, 2021 are as follows (unaudited, in thousands): Revenue $ 136,078 Net income $ 15,823 Valuation of Acquired Intangible Assets The valuation of acquired intangible assets is inherently subjective and relies on significant unobservable inputs. The Company uses an income approach to value acquired tradename/trademarks, licenses/customer base, and non-compete intangible assets. The valuation for each of these intangible assets was based on estimated projections of expected cash flows to be generated by the assets discounted to the present value at discount rates commensurate with perceived risk. The valuation assumptions take into consideration the Company’s estimates of new markets, products and customers and its outcome through key assumptions driving asset values, including sales growth, royalty rates and other related costs. Asset Purchases Green Growth In January 2022, the Company entered into a stock purchase agreement to acquire 100 % of the equity ownership of Green Growth Group Inc. (“Green Growth”), an entity that holds a craft cultivation and production cannabis license issued by the Illinois Department of Agriculture, in exchange for cash of $ 1.9 million and shares of the Company’s common stock valued at $ 1.5 million. Concurrently, the Company made a good faith deposit of $ 0.1 million. In April 2022, the Illinois Department of Agriculture approved the Company’s acquisition of Green Growth, and the Green Growth Acquisition was completed on the Green Growth Acquisition Date. The Company paid the remaining $ 1.8 million in cash and issued 2,343,750 shares of common stock to the sellers on the Green Growth Acquisition Date. With this license, the Company can cultivate up to 14,000 square feet of canopy to grow cannabis flower and produce cannabis concentrates. The Company has allocated the purchase price to its licenses/customer base intangible asset, with an estimated useful life of ten years . Greenhouse Naturals In November 2021, the Company entered into an asset purchase agreement with Greenhouse Naturals LLC (the "Greenhouse Naturals Sellers") to acquire the cannabis license and assume the property lease associated with a cannabis dispensary in Beverly, MA. The purchase transaction (the "Greenhouse Naturals Acquisition") was completed on December 30, 2022 (the "Greenhouse Naturals Acquisition Date"). The Company paid $ 0.1 million of cash and issued 2,000,000 shares of the Company's common stock, with a fair value of $ 0.7 million on the Greenhouse Naturals Acquisition Date, to the Sellers. The Company issued a note to the Greenhouse Naturals Sellers for the remaining $ 5.0 million of the cash purchase price payable post-closing on a monthly basis as a percentage of the dispensary's monthly gross sales (the "Greenhouse Naturals Note"). The Company has recorded the Greenhouse Naturals Note at present value of $ 4.3 million. The difference between the face value of the Greenhouse Naturals Note and the net present value recorded will be amortized to interest expense over the term of the note. The final inspection by the State of Massachusetts was completed in April 2023, and the Company opened the dispensary on April 25, 2023. The Company has allocated the purchase price to a licenses/customer base intangible asset, which has an estimated useful life of 10 years. 14 Table of Contents Pending Transactions Allgreens Dispensary, LLC ("Allgreens") In August 2022, the Company entered into an agreement to purchase 100 % of the membership interests in Allgreens Dispensary, LLC (the "Allgreens Agreement"), a conditional adult-use cannabis dispensary license in Illinois for $ 2,250,000 of cash. Completion of the acquisition is dependent upon certain conditions, including resolution of any remaining legal challenges affecting nearly 200 social equity dispensary licenses, and regulatory approval of the acquisition. Once the acquisition is complete, which the Company expects to occur in 2023, the Company will have five adult-use dispensaries operating in Illinois. Under the Allgreens Agreement, the Company has made payments aggregating $ 0.5 million to the Allgreens members, with additional cash payments aggregating $ 1,750,000 to be made as specific milestones are reached. The Company will issue promissory notes for the final payment of $ 1.0 million, which is due at closing (the "Allgreens Notes"). The Allgreens Notes will mature one year from the date the dispensary may begin operating. Robust Missouri Process and Manufacturing 1, LLC ("Robust") In September 2022, the Company entered into an agreement to acquire 100 % of the membership interests in Robust Missouri Processing and Manufacturing 1, LLC (the "Robust Agreement"), a Missouri wholesale and cultivator, for $ 0.7 million of cash. Completion of the acquisition is dependent upon obtaining all requisite approvals from the Missouri Department of Health and Senior Services, which is expected to occur in 2023. Under the Robust Agreement, the Company made an initial advance payment of $ 350,000 to the Robust members, with an additional payment of $ 350,000 to be made at closing. (3) (LOSS) EARNINGS PER SHARE Basic earnings per share is computed by dividing net income by the weighted average number of shares outstanding during the period. For periods in which the Company reports net income, diluted net income per share is determined by using the weighted average number of common and dilutive common equivalent shares outstanding during the period, unless the effect is antidilutive. The number of shares used to compute net (loss) earnings per share were as follows (in thousands): Three months ended March 31, 2023 March 31, 2022 Weighted average shares outstanding - basic 342,794 334,763 Potential dilutive common shares — 44,127 Weighted average shares outstanding - diluted 342,794 378,890 (4) DEFERRED RENTS RECEIVABLE The Company is the lessor under operating leases, which contain escalating rents over time, rent holidays, options to renew, requirements to pay property taxes, insurance and/or maintenance costs, and contingent rental payments based on a percentage of monthly tenant revenues. The Company is not the lessor under any finance leases. The Company recognizes fixed rental receipts from such lease agreements on a straight-line basis over the expected lease term. Differences between amounts received and amounts recognized are recorded in Deferred rents receivable in the condensed consolidated balance sheets. Contingent rentals are recognized only after tenants’ revenues are finalized and if such revenues exceed certain minimum levels. 15 Table of Contents The Company is the lessor of the following owned properties: • Delaware – a 45,000 square foot cannabis cultivation, processing, and dispensary facility which is leased to its cannabis-licensed client under a triple net lease that expires in 2035. • Maryland – a 180,000 square foot cultivation and processing facility that expires in 2037. This facility was leased to Kind prior to the Kind Acquisition Date. • Massachusetts – a 138,000 square foot industrial property, of which approximately half of the available square footage is leased to a non-cannabis manufacturing company (the "Tenant") under a lease that expired in February 2023. The Tenant currently continues to occupy this space on a month-to-month basis. The Company the sublessor of the following properties: • Delaware – a 4,000 square foot cannabis dispensary, which is subleased to its cannabis-licensed client under a sublease expiring in April 2027. • Delaware – a 100,000 square foot warehouse, of which the Company developed 60,000 square feet into a cultivation facility that is subleased to its cannabis-licensed client. The sublease expires in March 2030, with an option to extend the term for three additional five-year periods. The Company intends to develop the remaining space into a processing facility. • Delaware – a 12,000 square foot cannabis production facility with offices which is subleased to its cannabis-licensed client. The sublease expires in January 2026 and contains an option to negotiate an extension at the end of the lease term. The Company received rental payments aggregating $ 0.4 million and $ 1.2 million in the three months ended March 31, 2023 and 2022, respectively. Revenue from these payments was recognized on a straight-line basis and aggregated $ 0.4 million and $ 1.1 million in the three months ended March 31, 2023 and 2022, respectively. Future minimum rental receipts for non-cancellable leases and subleases as of March 31, 2023 were as follows (in thousands): Year ending December 31, Remainder of 2023 $ 1,159 2024 1,357 2025 1,357 2026 1,221 2027 1,134 Thereafter 4,550 $ 10,778 (5) NOTES RECEIVABLE Notes receivable, including accrued interest, at March 31, 2023 and December 31, 2022 consisted of the following (in thousands): March 31, 2023 December 31, 2022 First State Compassion Center (FSCC Initial Note) $ 308 $ 328 First State Compassion Center (FSCC Secondary Notes) 8,238 8,160 First State Compassion Center (FSCC New Note) 750 750 Healer LLC 866 866 Total notes receivable 10,162 10,104 Less: Notes receivable, current portion ( 2,639 ) ( 2,637 ) Notes receivable, less current portion $ 7,523 $ 7,467 16 Table of Contents First State Compassion Center The Company’s cannabis-licensed client in Delaware, First State Compassion Center (“FSCC”), issued a 10 -year promissory note to the Company in May 2016 for $ 0.7 million, bearing interest at a rate of 12.5 % per annum and maturing in April 2026, as amended (the “FSCC Initial Note”). The monthly payments on the FSCC Initial Note approximate $ 10,000 . At March 31, 2023 and December 31, 2022, the current portions of the FSCC Initial Note were approximately $ 87,000 and $ 85,000 , respectively, and were included in Notes receivable, current, in the condensed consolidated balance sheets. In December 2021, the Company converted financed trade accounts receivable balances from FSCC aggregating $ 7.8 million into notes receivable, whereby FSCC issued promissory notes aggregating $ 7.8 million to the Company (the “FSCC Secondary Notes”). The FSCC Secondary Notes bear interest of 6.0 % per annum and mature in December 2025. FSCC is required to make periodic payments of principal and interest throughout the term of the FSCC Secondary Notes. At March 31, 2023 and December 31, 2022, the FSCC Secondary Notes balance included approximately $ 28,000 and $ 49,000 , respectively, of unpaid accrued interest. The increase in the FSCC Secondary Notes in the three months ended March 31, 2023 was attributable to the accreted interest, which increases the value of such notes. At each of March 31, 2023 and December 31, 2022, the current portions of the FSCC Secondary Notes aggregated $ 2.5 million. In December 2022, the Company converted a short-term loan and other receivable balances from FSCC aggregating $ 750,000 into a note receivable, whereby FSCC issued a promissory note to the Company for $ 750,000 (the "FSCC New Note"). The FSCC New Note bears interest of 6.0 % per annum and matures in December 2026. FSCC is required to make quarterly interest payments, with the full amount of principal due on December 31, 2026. At each of March 31, 2023 and December 31, 2022, the entire balance of the FSCC New Note was long-term. Healer LLC In March 2021, the Company was issued a promissory note in the principal amount of approximately $ 0.9 million from Healer LLC, an entity that provides cannabis education, dosage programs, and products developed by Dr. Dustin Sulak (“Healer”). The principal balance of the note represents previous loans extended to Healer by the Company of $ 0.8 million, plus accrued interest through the revised promissory note issuance date of approximately $ 94,000 (the “Revised Healer Note”). The Revised Healer Note bears interest at a rate of 6.0 % per annum and requires quarterly payments of interest through the April 2026 maturity date. The Company has the right to offset any licensing fees payable by the Company to Healer in the event Healer fails to make any payment when due. In March 2021, the Company offset approximately $ 28,000 of licensing fees payable to Healer against the principal balance of the Revised Healer Note, reducing the principal amount to approximately $ 866,000 . Of the outstanding Revised Healer Note balance at each of March 31, 2023 and December 31, 2022, approximately $ 52,000 was current. (6) INVENTORY Inventory at March 31, 2023 and December 31, 2022 consisted of the following (in thousands): March 31, 2023 December 31, 2022 Plants $ 2,511 $ 2,653 Ingredients and other raw materials 4,310 3,255 Work-in-process 9,039 7,635 Finished goods 6,863 5,934 $ 22,723 $ 19,477 17 Table of Contents (7) INVESTMENTS The Company’s investment at March 31, 2023 and December 31, 2022 was classified as current and was comprised of the following (in thousands): March 31, 2023 December 31, 2022 WM Technology Inc. $ 104 $ 123 The Company did not have any long-term investments at March 31, 2023 or December 31, 2022. WM Technology Inc. In February 2022, the Company received 121,968 shares of common stock of WM Technology Inc. (Nasdaq: MAPS) (the "WMT Shares"), a technology and software infrastructure provider to the cannabis industry, which represented the Company’s pro rata share of additional consideration pursuant to a 2021 asset purchase agreement between the Company and Members RSVP LLC. The Company recognized a loss of approximately $ 19,000 in the three months ended March 31, 2023, which reflects the change in the fair value of the WMT Shares for the period. The fair value of the WMT Shares was approximately $ 954,000 at March 31, 2022. Both the loss in the three months ended March 31, 2022 from the change in the fair value of the WMT Shares and the gain arising from the receipt of the WMT Shares are reported as Other (expense) income, net, in the condensed consolidated statements of operations for the respective periods. Flowr Corp. In December 2021, the Company received shares of Flowr Corp. common stock (the "Flowr Stock") arising from the sale of its ownership interest in Terrace Inc., which was sold to Flowr Corp. (TSX.V: FLWR; OTC: FLWPF). The Flowr Stock was recorded at fair value, with changes in fair value recorded as a component of Other (expense) income net, in the condensed consolidated statements of operations. The Company recorded a gain of approximately $ 48,000 in the three months ended March 31, 2022, which represented the change in the fair value of the Flowr Stock for the period. In the fourth quarter of 2022, the Company wrote off the remaining fair value of the Flower Stock arising from Flowr Corp.'s bankruptcy filing and delisting from the exchange on which its stock was traded. (8) PROPERTY AND EQUIPMENT, NET The Company’s property and equipment, net, at March 31, 2023 and December 31, 2022 was comprised of the following (in thousands): March 31, 2023 December 31, 2022 Land $ 4,450 $ 4,450 Buildings and building improvements 43,075 43,542 Tenant improvements 16,790 17,016 Furniture and fixtures 1,981 2,009 Machinery and equipment 10,223 10,087 Construction in progress 7,343 4,761 83,862 81,865 Less: accumulated depreciation ( 10,148 ) ( 10,224 ) Property and equipment, net $ 73,714 $ 71,641 The Company recorded $ 1.0 million and $ 0.7 million of depreciation expense related to property and equipment in the three months ended March 31, 2023 and 2022, respectively. The Company disposed of equipment it had previously purchased in connection with its planned acquisition of The Harvest Foundation LLC ("Harvest") in Nevada as a result of the Company's withdrawal from the agreement to purchase Harvest. The Company recorded a loss on these asset disposals aggregating $ 0.9 million, which is included as a component of Other (expense) income, net, in the condensed consolidated statement of operation for the three months ended March 31, 2023. 18 Table of Contents (9) INTANGIBLE ASSETS AND GOODWILL The Company’s acquired intangible assets at March 31, 2023 and December 31, 2022 consisted of the following (in thousands): March 31, 2023 Weighted average amortization period (years) Cost Accumulated amortization Net carrying value Tradename and trademarks 7.11 $ 3,104 $ 624 $ 2,480 Licenses and customer base 9.22 18,033 1,056 16,977 Non-compete agreements 2.00 42 19 23 8.89 $ 21,179 $ 1,699 $ 19,480 December 31, 2022 Weighted average amortization period (years) Cost Accumulated amortization Net carrying value Tradename and trademarks 3.00 $ 2,041 $ 453 $ 1,588 Licenses and customer base 8.94 13,260 675 12,585 Non-compete agreements 2.00 42 14 28 8.13 $ 15,343 $ 1,142 $ 14,201 Estimated future amortization expense for the Company’s intangible assets at March 31, 2023 was as follows: Year ending December 31, Remainder of 2023 $ 2,023 2024 2,683 2025 2,223 2026 1,996 2027 1,996 Thereafter 8,559 Total $ 19,480 The changes in the carrying value of the Company’s goodwill in the three months ended March 31, 2023 and 2022 were as follows (in thousands): 2023 2022 Balance at January 1, $ 8,079 $ 2,068 Ermont Acquisition 3,925 — Balance at March 31, $ 12,004 $ 2,068 (10) Term Loan Credit Agreement On January 24, 2023, the Company entered into a Loan and Security Agreement, by and among the Company, subsidiaries of the Company from time-to-time party thereto (collectively with the Company, the “Borrowers”), lenders from time-to-time party thereto (the “Lenders”), and Chicago Atlantic Admin, LLC (“Chicago Atlantic”), as administrative agent for the Lenders (the "Credit Agreement"). 19 Table of Contents Proceeds from the Credit Agreement are designated to complete the build-out of a new cultivation and processing facility in Illinois, complete the build-out of a new processing kitchen in Missouri, expand existing cultivation and processing facilities in Massachusetts and Maryland, fund certain capital expenditures, and repay in full the Kind Therapeutics seller notes incurred in connection with the Kind Acquisition, which repayment occurred on January 24, 2023 (see Note 11). The remaining balance, if any, is expected to be used to fund acquisitions. Principal, Security, Interest and Prepayments The Credit Agreement provides for $ 35.0 million in principal borrowings at the Borrowers’ option in the aggregate and further provides the Borrowers with the right, subject to customary conditions, to request an additional incremental term loan in the aggregate principal amount of up to $ 30.0 million, provided that the Lenders elect to fund such incremental term loan. $ 30.0 million of loan principal was funded at the initial closing (the "Term Loan"), which amount was reduced by an original issuance discount of $ 0.9 million. The Company has the option, during a six-month period following the initial closing, to draw down an additional $ 5.0 million. The loans require scheduled amortization payments of 1.0 % of the principal amount outstanding under the Credit Agreement per month commencing in May 2023, and the remaining principal balance is due in full on January 24, 2026, subject to extension to January 24, 2028 under certain circumstances. The Credit Agreement provides the Borrowers with the right, subject to specified limitations, to (a) incur seller provided debt in connection with future acquisitions, (b) incur additional mortgage financing from third-party lenders secured by real estate currently owned and acquired after the closing date, and (c) to incur additional debt in connection with equipment leasing transactions. The obligations under the Credit Agreement are secured by substantially all of the assets of the Borrowers, excluding specified parcels of real estate and other customary exclusions. The Credit Agreement provides for a floating annual interest rate equal to the prime rate then in effect plus 5.75 %, which rate may be increased by 3.00 % upon an event of default or 7.50 % upon a material event of default as provided in the Credit Agreement. At any time, the Company may voluntarily prepay amounts due under the facility in $ 5.0 million increments, subject to a three -percent prepayment premium and, during the first 20 -months of the term, a “make-whole” payment. Representations, Warranties, Events of Default and Certain Covenants The Credit Agreement includes customary representations and warranties and customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to material indebtedness, and events of bankruptcy and insolvency. The Credit Agreement also includes customary negative covenants limiting the Borrowers’ ability to incur additional indebtedness and grant liens that are otherwise not permitted, among others. Additionally, the Credit Agreement requires the Borrowers to meet certain financial tests. At March 31, 2023, the Company was in compliance with the Credit Agreement covenants. Warrant Issuance The Credit Agreement provides for 30 % warrant coverage against amounts funded under the facility, priced at a 20 % premium to the trailing 20 -day average price on the closing date of each such funding. At the initial closing, upon funding of the initial $ 30.0 million under the facility, the Company issued to the Lenders an aggregate of 19,148,936 warrants to purchase shares of the Company’s common stock at $ 0.47 per share, exercisable for a five-year period following issuance. Incremental warrants are issuable upon further draw-downs under the facility. The Company recorded the warrants at present value of $ 5.5 million as a component of Additional paid-in capital on the condensed consolidated balance sheet as of January 24, 2023, and discounted the Term Loan by $ 5.5 million (the "Term Loan Discount"). The Term Loan Discount is being amortized to interest expense over the term of the Credit Agreement. The Company recorded $ 0.3 million of interest amortization for the three months ended March 31, 2023. 20 Table of Contents Outstanding Balance At March 31, 2023, the outstanding Term Loan balance reported on the Company's condensed consolidated balance sheet was $ 24.1 million, with the current portion totaling $ 3.3 million. (11) MORTGAGES AND NOTES PAYABLE The Company’s mortgages and notes payable are reported in the aggregate on the condensed consolidated balance sheets under the captions Mortgages and notes payable, current, and Mortgages and notes payable, net of current. Mortgages The Company’s mortgage balances at March 31, 2023 and December 31, 2022 were comprised of the following (in thousands): March 31, 2023 December 31, 2022 Bank of New England – New Bedford, MA and Middleboro, MA properties $ 12,038 $ 12,141 Bank of New England – Wilmington, DE property 1,313 1,345 DuQuoin State Bank – Anna, IL and Harrisburg, IL properties 741 750 DuQuoin State Bank – Metropolis, IL property 2,474 2,508 Du Quoin State Bank - Mt. Vernon, IL property 2,957 2,974 South Porte Bank – Mt. Vernon, IL property 784 801 Total mortgages payable 20,307 20,519 Less: Mortgages payable, current ( 1,483 ) ( 1,491 ) Mortgages payable, less current portion $ 18,824 $ 19,028 The Company maintains an amended and restated mortgage agreement with the Bank of New England with an interest rate of 6.5 % per annum, which matures in August 2025 (the “Amended BNE Mortgage”). The Amended BNE Mortgage is secured by the Company’s properties in New Bedford, Massachusetts and Middleboro, Massachusetts. Proceeds from the Amended BNE Mortgage were used to pay down a previous mortgage of $ 4.8 million with the Bank of New England on the New Bedford property, and $ 7.2 million of outstanding promissory notes as discussed below. The current portions of the outstanding principal balance under the Amended BNE Mortgage at March 31, 2023 and December 31, 2022 were approximately $ 387,000 and $ 382,000 , respectively. The Company maintains a second mortgage with Bank of New England that is secured by the Company’s property in Wilmington, Delaware (the “BNE Delaware Mortgage”). The mortgage matures in 2031, with monthly principal and interest payments. The interest rate is 5.25 % per annum, with the rate adjusting every five years to the then-prime rate plus 1.5 %, with a floor of 5.25 % per annum. The next interest rate adjustment will occur in September 2026. The current portions of the outstanding principal balance under the BNE Delaware Mortgage at March 31, 2023 and December 31, 2022 were approximately $ 128,000 and $ 126,000 , respectively. The Company maintains a mortgage with DuQuoin State Bank (“DSB”) in connection with its purchase of properties in Anna, Illinois and Harrisburg, Illinois (the “DuQuoin Mortgage”). On May 5th of each year, the DuQuoin Mortgage becomes due unless it is renewed for another year at a rate determined by DSB’s executive committee. The DuQuoin Mortgage was renewed in May 2021 at a rate of 6.75 % per annum. The current portions of the outstanding principal balance under the DuQuoin Mortgage at each of March 31, 2023 and December 31, 2022 were approximately $ 37,000 and $ 36,000 , respectively. In July 2021, the Company purchased the land and building in which it operates its cannabis dispensary in Metropolis, Illinois. The purchase price consisted of 750,000 shares of the Company’s common stock, which were valued at $ 705,000 on the date of the transaction, and payoff of the seller’s remaining mortgage balance of $ 1.6 million. In connection with this purchase, the Company entered into a second mortgage agreement with DSB for $ 2.7 million that matures in July 2041, and which initially bears interest at a rate of 6.25 % per annum (the “DuQuoin Metropolis Mortgage”). The interest rate on the DuQuoin Metropolis Mortgage is adjusted each year based on a certain interest rate index plus a margin. As part of this transaction, the seller was provided with a 30.0 % ownership interest in Mari Holdings Metropolis LLC (“Metro”), the Company’s subsidiary that owns the property and holds the related mortgage obligation, reducing the 21 Table of Contents Company’s ownership interest in Metro to 70.0 %. The current portions of the outstanding principal balance of the DuQuoin Metropolis Mortgage at March 31, 2023 and December 31, 2022 were approximately $ 79,000 and $ 77,000 , respectively. In July 2022, Mari Holdings Mt Vernon LLC, a wholly owned subsidiary of the Company, entered into a $ 3 million loan agreement and mortgage with DSB secured by property owned in Mt. Vernon, Illinois, which the Company is developing into a grow and production facility (the "DuQuoin Mt. Vernon Mortgage"). The DuQuoin Mt. Vernon Mortgage has a 20 -year term and initially bears interest at the rate of 7.75 % per annum, subject to upward adjustment on each annual anniversary date to the Wall Street Journal U.S. Prime Rate (with an interest rate floor of 7.75 %). The proceeds of this loan are being utilized for the build-out of the property and other working capital needs. The current portions of the outstanding principal balance of the DuQuoin Mt. Vernon Mortgage were approximately $ 68,000 at each of March 31, 2023 and December 31, 2022. In February 2020, the Company entered into a mortgage agreement with South Porte Bank for the purchase and development of a property in Mt. Vernon, Illinois, (the “South Porte Bank Mortgage”). Beginning in August 2021, pursuant to an amendment of the South Porte Bank Mortgage, the monthly payments of principal and interest aggregated approximately $ 6,000 , with such payment amounts effective through June 2023, at which time all remaining principal, interest and fees are due. Promissory Notes Promissory Notes Issued as Purchase Consideration Ermont Acquisition In connection with the Ermont Acquisition, the Company issued the Ermont Note (see Note 2) totaling $ 7.0 million. The Ermont Note matures in March 2029, and bears interest at 6.0 % per annum, with payments of interest only for two years , and thereafter quarterly payments of principal and interest in arrears. The outstanding balance on the Ermont Note is due and payable in full if and when the Company raises $ 75 million or more of equity capital. The Company recorded the Ermont Note at a present value of $ 4.6 million. The Company recorded $ 2.4 million as a debt discount, which is being accreted through the term of the Ermont Note. The difference between the face value of the Ermont Note and the present value recorded at the time of the Ermont Acquisition is being amortized to interest expense over the term of the Ermont Note. The fair value of the Ermont Note was $ 4.6 million at March 31, 2023, all of which was recorded as noncurrent, as the first principal payment is not due until two years after the Ermont Acquisition Date. Greenhouse Naturals Acquisition In connection with the Greenhouse Naturals Acquisition, the Company issued the Greenhouse Naturals Note (see Note 2) totaling $ 5.0 million to the Greenhouse Sellers, payable on a monthly basis as a percentage of the monthly gross sales of the Company's Beverly, Massachusetts dispensary. The Company recorded the Greenhouse Naturals Note at a present value of $ 4.3 million. The Company recorded $ 0.7 million as a debt discount, which is being accreted through the term of the Greenhouse Naturals Note. The difference between the face value of the Greenhouse Naturals Note and the present value recorded at the time of the Greenhouse Naturals Acquisition is being amortized to interest expense over the term of the note, which matures in July 2026. The fair values of the Greenhouse Naturals Note were $ 4.4 million and $ 4.3 million at March 31, 2023 and December 31, 2022, respectively. The Company estimated that the current portions of the Greenhouse Naturals Note were $ 1.3 million and $ 0.9 million at March 31, 2023 and December 31, 2022, respectively, which are included in Mortgages and notes payable, current portion, in the Company's condensed consolidated balance sheets. Kind Acquisition In connection with the Kind Acquisition (see Note 2), the Company issued four-year promissory notes aggregating $ 6.5 million at the rate of 6.0 % per annum to the members of Kind (the “Kind Notes”). At December 31, 2022, the outstanding balance of the Kind Notes totaled $ 5.5 million, of which $ 1.6 million was current. On January 24, 2023, in connection with the Credit Agreement (see Note 10), the Company repaid the Kind Notes in full, aggregating $ 5.4 million, including approximately $ 420,000 of accrued interest. There was no penalty in connection with the early repayment of the Kind Notes. 22 Table of Contents Promissory Note Conversion During the three months ended March 31, 2022, a noteholder converted the outstanding principal balance of $ 400,000 into 1,142,858 shares of the Company’s common stock and the note was retired. The Company did not record any gains or losses arising from this conversion. Promissory Notes Issued to Purchase Commercial Vehicles The Company purchased a commercial vehicle in January 2023 and entered into a note agreement with Ally Financial to finance the purchase. The Company had previously entered into note agreements to purchase commercial vehicles in August 2020 with First Citizens' Federal Credit Union and in June 2021 with Ally Financial. At March 31, 2023, the three outstanding notes had an aggregate outstanding balance of approximately $ 95,000 , of which approximately $ 17,000 was current. At December 31, 2022, the two outstanding notes had an aggregate outstanding balance of approximately $ 48,000 , of which approximately $ 12,000 was current. The weighted average interest rates of the outstanding balances were 11.64 % and 8.19 % at March 31, 2023 and December 31, 2022, respectively. The weighted average remaining terms of these notes were 4.84 years and 4.07 years at March 31, 2023 and December 31, 2022, respectively. Future Payments The future principal amounts due under the Company outstanding mortgages and notes payable at March 31, 2023 were as follows (in thousands): Year ending December 31, Remainder of 2023 $ 1,426 2024 3,047 2025 3,810 2026 3,578 2027 2,677 Thereafter 17,984 32,522 Less: discount ( 3,139 ) $ 29,383 (12) MEZZANINE EQUITY Series B Convertible Preferred Stock In 2021, the Company entered into an exchange agreement with two unaffiliated institutional shareholders (the “Exchange Agreement”) whereby the Company (i) issued $ 4.4 million of promissory notes to the two institutional shareholders, which were retired in March 2021, and (ii) exchanged 4,908,333 shares of the Company’s common stock previously acquired by the two institutional shareholders for an equal number of shares of newly designated Series B convertible preferred stock (the “Series B Stock”). In connection with the Exchange Agreement, the Company filed (i) a certificate of designation with respect to the rights and preferences of the Series B Stock, and (ii) a certificate of elimination to return all shares of the Series A convertible preferred stock, of which no shares were issued or outstanding at the time of filing, to the status of authorized and unissued shares of undesignated preferred stock. The holders of Series B Stock (the “Series B Holders”) are entitled to cast the number of votes equal to the number of shares of the Company's common stock into which the shares of Series B Stock are convertible, together with the holders of the Company's common stock as a single class, on most matters. However, the affirmative vote or consent of the Series B Holders voting separately as a class is required for certain acts taken by the Company, including the amendment or repeal of certain charter provisions, liquidation or winding up of the Company, creation of stock senior to the Series B Stock, and/or other acts defined in the certificate of designation. 23 Table of Contents The Series B Stock shall, with respect to dividend rights and rights on liquidation, winding up and dissolution, rank senior to the Company’s common stock. The Company shall not declare, pay, or set aside any dividends on shares of any other class or series of capital stock of the Company unless the Series B Holders shall first receive, or simultaneously receive, a dividend on each outstanding share of Series B Stock in an amount calculated pursuant to the certificate of designation. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the Series B Holders shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of the Company's common stock by reason of their ownership thereof, an amount per share of Series B Stock equal to $ 3.00 , plus any dividends declared but unpaid thereon, with any remaining assets distributed pro-rata among the Series B Holders and the holders of the Company's common stock, based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to shares of the Company's common stock. At any time on or prior to the six-year anniversary of the issuance date of the Series B Stock, (i) the Series B Holders have the option to convert their shares of Series B Stock into shares of the Company's common stock at a conversion price of $ 3.00 per share, without the payment of additional consideration, and (ii) the Company has the option to convert all, but not less than all, shares of Series B Stock into shares of the Company's common stock at a conversion price of $ 3.00 if the daily volume weighted average price of the Company's common stock (the “VWAP”) exceeds $ 4.00 per share for at least twenty consecutive trading days prior to the date on which the Company gives notice of such conversion to the Series B Holders. On the day following the six-year anniversary of the issuance of the Series B convertible preferred stock, all outstanding shares of Series B Stock shall automatically convert into shares of the Company's common stock as follows: • If the sixty-day VWAP is less than or equal to $ 0.50 per share, the Company shall have the option to (i) convert all shares of Series B Stock into shares of the Company's common stock at a conversion price of $ 1.00 per share, and pay cash to the Series B Holders equal to the difference between the sixty-day VWAP and $ 3.00 per share, or (ii) pay cash to the Series B Holders equal to $ 3.00 per share. • If the sixty-day VWAP is greater than $ 0.50 per share, the Company shall have the option to (i) convert all shares of Series B Stock into shares of the Company's common stock at a conversion price per share equal to the quotient of $ 3.00 per share divided by the sixty-day VWAP, or (ii) pay cash to the Series B Holders equal to $ 3.00 per share, or (iii) convert all shares of Series B Stock into shares of the Company's common stock at a conversion price per share equal to the sixty-day VWAP and pay cash to the Series B Holders equal to the difference between $ 3.00 per share and the sixty-day VWAP. The Company shall at all times when the Series B Stock is outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Series B Stock, such number of its duly authorized shares of common stock as shall from time to time be sufficient to effect the conversion of all outstanding Series B Stock. Series C Convertible Preferred Stock In March 2021, the Company entered into a securities purchase agreement with Hadron Healthcare Master Fund (“Hadron”) with respect to a financing facility of up to $ 46.0 million (the “Hadron Facility”) in exchange for newly-designated Series C convertible preferred stock of the Company (the “Series C Stock”) and warrants to purchase the Company’s common stock (the “Hadron Transaction”). At the closing of the Hadron Transaction in March 2021, Hadron purchased $ 23.0 million of Units at a price of $ 3.70 per Unit. Each Unit is comprised of one share of Series C Stock and a four-year warrant to purchase two and one-half shares of the Company's common stock. The Company issued to Hadron 6,216,216 shares of Series C Stock and warrants to purchase up to an aggregate of 15,540,540 shares of its common stock. Each share of Series C Stock is convertible, at Hadron’s option, into five shares of the Company's common stock, and each warrant is exercisable at an exercise price of $ 1.087 per share. The warrants are subject to early termination if certain milestones are achieved and the market value of the Company’s common stock reaches certain predetermined levels. The fair value of the warrants on the issuance date was $ 9.5 million, which amount was recorded in Additional paid-in capital. The Company incurred costs of $ 0.4 million related to the issuance of these securities, which was recorded as a reduction to Additional paid-in capital in March 2021. 24 Table of Contents In connection with the closing of the Hadron Transaction, the Company filed a certificate of designation with respect to the rights and preferences of the Series C Stock. Such stock is zero coupon, non-voting, and has a liquidation preference equal to its original issuance price plus declared but unpaid dividends. Holders of Series C Stock are entitled to receive dividends on an as-converted basis. Of the $ 23.0 million of proceeds received by the Company in March 2021, $ 7.3 million was used to fund construction and upgrades to certain of the Company’s owned and managed facilities, and $ 15.7 million was used to pay down debt and related interest (see Note 11). No further funding has occurred under the Hadron Facility and, on August 4, 2022, the Company and Hadron entered into a Second Amendment to the Securities Purchase Agreement pursuant to which, inter alia, (a) Hadron’s obligation to provide any further funding to the Company and the Company’s obligation to sell any further securities to Hadron was terminated, (b) Hadron’s right to appoint a designee to the Company’s board of directors was eliminated, and (c) certain covenants restricting the Company’s incurrence of new indebtedness were eliminated. (13) STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Amended and Restated 2018 Stock Award and Incentive Plan The Company’s Amended and Restated 2018 Stock Award and Incentive Plan (the “2018 Plan”) provides for the award of options to purchase the Company’s common stock (“stock options”), restricted stock units ("RSUs"), stock appreciation rights (“SARs”), restricted stock, deferred stock, dividend equivalents, performance shares or other stock-based performance awards and other stock- or cash-based awards. Awards can be granted under the 2018 Plan to the Company’s employees, officers and non-employee directors, as well as consultants and advisors of the Company and its subsidiaries. Stock Options A summary of the Company's stock option activity during the three months ended March 31, 2023 is below: Shares Weighted average exercise price Outstanding at January 1, 2023 36,504,673 $ 0.82 Granted 1,100,000 $ 0.43 Forfeited ( 457,500 ) $ 1.97 Outstanding at March 31, 2023 37,147,173 $ 0.80 Stock options granted under the 2018 Plan generally expire five years from the date of grant. At March 31, 2023, the options outstanding had a weighted average remaining life of approximately three years . The grant date fair values of stock options granted in the three months ended March 31, 2023 were estimated using the Black-Scholes valuation model with the following assumptions: Estimated life (in years) 3.00 to 3.26 Weighted average volatility 99.22 % Weighted average risk-free interest rate 3.59 % Dividend yield — Restricted Stock Units The Company began to grant RSUs under the 2018 Plan in the fourth quarter of 2022. Holders of unvested RSUs do not have voting and dividend rights. The grant date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service periods. The fair value of RSUs is determined based on the market value of the shares of the Company's common stock on the date of grant. 25 Table of Contents The activity related to the Company's RSUs for the three months ended March 31, 2023 was as follows: RSUs Weighted average grant date fair value Unvested at January 1, 2023 1,599,999 $ 0.53 Granted 1,108,000 $ 0.46 Outstanding at March 31, 2023 2,707,999 $ 0.50 Warrants In connection with the Credit Agreement, the Company issued to the Lenders an aggregate of 19,148,936 warrants to purchase shares of the Company's common stock at $ 0.47 per share, exercisable for a five-year period following issuance (see Note 10). At March 31, 2023, warrants to purchase up to 41,824,476 shares of the Company's common stock were outstanding, with a weighted average exercise price of $ 1.46 . Other Common Stock Issuances In addition to the activity described previously, the Company also issued during the three months ended March 31, 2023: • 70,000 shares of restricted common stock reported as subscribed at December 31, 2022 as discussed below; • 6,580,390 shares of restricted common stock with a fair value of $ 3.0 million issued as purchase consideration for the Ermont Acquisition (see Note 2); and • 1,793 shares of restricted common stock with an aggregate fair value of approximately $ 1,000 issued under a royalty agreement. Stock-Based Compensation The Company recorded stock-based compensation of $ 0.2 million and $ 2.5 million in the three months ended March 31, 2023 and 2022, respectively. Common Stock Issuance Obligations At March 31, 2023, the Company was obligated to issue 5,025 shares of restricted common stock with an aggregate grant date fair value of approximately $ 2,000 to an employee. At December 31, 2022, the Company was obligated to issue 70,000 shares of restricted common stock in the aggregate with a total grant date fair value of approximately $ 39,000 , to two employees, which were issued during the three months ended March 31, 2023. (14) REVENUE The Company’s main sources of revenue are comprised of the following: • Product sales (retail and wholesale) – direct sales of cannabis and cannabis-infused products by the Company’s retail dispensaries and wholesale operations. This revenue is recognized when products are delivered or at retail points-of-sale. • Real estate rental income – rental income generated from leasing of the Company’s state-of-the-art, regulatory-compliant cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the respective lease terms. Prior to the third quarter of 2022, the Company charged additional rental fees based on a percentage of tenant revenues that exceeded specific amounts; these incremental rental fees were eliminated in connection with new contract terms with the Company's client. • Supply procurement – resale of cultivation and production resources, supplies and equipment that the Company has acquired from top national vendors at discounted prices to its client and third parties within the cannabis 26 Table of Contents industry. The Company recognizes this revenue after the delivery and acceptance of goods by a purchaser. • Management fees – fees for providing the Company’s cannabis clients with comprehensive oversight of their cannabis cultivation, production and dispensary operations. Prior to the third quarter of 2022, these fees were based on a percentage of such client's revenue and were recognized after services were performed; these fees were eliminated in connection with new contract terms with the Company's client. • Licensing fees – revenue from the licensing of the Company's branded products, including Betty's Eddies , Bubby's Baked , Vibations and Kalm Fusion , to wholesalers and to regulated dispensaries throughout the United States and Puerto Rico. The Company recognizes this revenue when the products are delivered. The Financial Accounting Standards Board Accounting Standards Codification 606, Revenue from Contract with Customers, as amended by subsequently issued Accounting Standards Updates, requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. The recognition of revenue is determined by performing the following consecutive steps: • Identify the contract(s) with a customer; • Identify the performance obligations in the contract(s); • Determine the transaction price; • Allocate the transaction price to the performance obligations in the contract(s); and • Recognize revenue as the performance obligation is satisfied. Additionally, when another party is involved in providing goods or services to the Company’s clients, a determination is made as to who - the Company or the other party - is acting in the capacity as the principal in the sale transaction, and who is the agent arranging for goods or services to be provided by the other party. The Company is typically considered the principal if it controls the specified good or service before such good or service is transferred to its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations, and risks, (ii) possesses certain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance obligations it does not satisfy. Revenue for the three months ended March 31, 2023 and 2022 was comprised of the following (in thousands): Three months ended March 31, 2023 March 31, 2022 Product revenue: Product revenue - retail $ 23,183 $ 21,441 Product revenue - wholesale 10,376 6,062 Total product revenue 33,559 27,503 Other revenue: Real estate rentals 420 1,587 Supply procurement 308 1,190 Management fees 19 753 Licensing fees 74 249 Total other revenue 821 3,779 Total revenue $ 34,380 $ 31,282 (15) MAJOR CUSTOMERS The Company did not have any customers that contributed 10% or more of total revenue in either of the three-month periods ended March 31, 2023 or 2022. 27 Table of Contents The Company did not have any customers that accounted for 10% or more of the Company’s accounts receivable balance, at either March 31, 2023 or December 31, 2022. The Company performs ongoing credit evaluations of its customers and generally does not require collateral on accounts receivable. The Company maintains an allowance for doubtful accounts and historical losses have been within management’s expectations. (16) LEASES Arrangements that are determined to be leases with a term greater than one year are accounted for by the recognition of right-of-use assets that represent the Company’s right to use an underlying asset for the lease term, and lease liabilities that represent the Company’s obligation to make lease payments arising from the lease. Non-lease components within lease agreements are accounted for separately. Right-of-use assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company is currently the lessee under seven operating leases and eleven finance leases. These leases contain rent holidays and customary escalations of lease payments for the type of facilities being leased. The Company recognizes rent expense on a straight-line basis over the expected lease term, including cancelable option periods which the Company fully expects to exercise. Certain leases require the payment of property taxes, insurance and/or maintenance costs in addition to the rent payments. The Company leases the following facilities under operating leases: • Delaware – 4,000 square feet of retail space in a multi-use building under a five-year lease that expires in April 2027 that the Company has developed into a cannabis dispensary which is subleased to its cannabis-licensed client. • Delaware – a 100,000 square foot warehouse, of which the Company developed 60,000 square feet into a cultivation facility that is being subleased to its cannabis-licensed client. The lease expires in March 2030, with an option to extend the term for three additional years. • Delaware – a 12,000 square foot premises, which the Company developed into a cannabis production facility with offices and which it subleases to its cannabis-licensed client. The lease expires in January 2026 and contains an option to negotiate an extension at the end of the lease. • Massachusetts – 10,000 square feet of office space, which the Company utilizes as its corporate offices under a lease with a related party expiring in 2028 with an option to extend the term for an additional five-year period. • Massachusetts - a 2,700 square foot dispensary, which lease the Company assumed under a lease that expires in 2026, with options to extend the term for three additional five-year periods through 2041. • Massachusetts - an approximately 33,800 square foot building which houses both a dispensary and a cultivation facility, which lease expires in October 2038. • Maryland – a 2,700 square foot two-unit apartment under a lease that expires in July 2023. The Company leases machinery and office equipment under finance leases that expire from July 2023 through January 2028, with such terms being a major part of the economic useful life of the leased property. 28 Table of Contents The components of lease expense for the three months ended March 31, 2023 and 2022 were as follows (in thousands): Three months ended March 31, 2023 March 31, 2022 Operating lease expense $ 299 $ 277 Finance lease expenses: Amortization of right of use assets $ 54 $ 19 Interest on lease liabilities 15 7 Total finance lease expense $ 69 $ 26 At March 31, 2023, the weighted average remaining lease terms for operating leases and finance leases were 10.2 years and 3.3 years, respectively. The weighted average discount rate used to determine the right-of-use assets and lease liabilities was between 7.5 % and 13.5 % for all leases. Future minimum lease payments as of March 31, 2023 under all non-cancelable leases having an initial or remaining term of more than one year were (in thousands): Operating leases Finance leases Remainder of 2023 $ 1,329 $ 273 2024 1,887 307 2025 1,929 306 2026 1,856 103 2027 1,754 46 Thereafter 3,953 — Total lease payments 12,708 1,035 Less: imputed interest ( 2,073 ) ( 175 ) $ 10,635 $ 860 In November 2021, the Company entered into lease agreements for six retail properties, each with square footage between 4,000 and 6,000 square feet, in the state of Ohio (each an “Ohio Lease” and collectively the “Ohio Leases”). Each Ohio Lease had an initial lease period of eleven months , with a minimum rent of $ 31.00 per square foot, which increased 3.0 % annually. Should the Company be awarded one or more cannabis licenses by the state of Ohio prior to the end of the initial lease period, it could extend the term of one or more of the Ohio Leases to ten years (with two additional five-year options to extend) upon the payment of $ 50,000 for the extended Ohio Lease, which the Company is building out into a medical use dispensary. In February 2022, the Company was notified that it was awarded a cannabis dispensary license from the state of Ohio. The Company is awaiting the final verification process to be completed by the state. In April 2022, the Company extended the term of one of the Ohio Leases to February 2023 (the "Extended Ohio Lease"), and the remaining five Ohio Leases were terminated. The Company intends to enter into a ten-year lease on the Extended Ohio Lease property, which will become effective upon the completion of the final verification process by the state. At March 31, 2023 and December 31, 2022, the lease term of the Extended Ohio Lease was less than one year, and the Company was not required to record a right-of-use asset and corresponding lease liability on its balance sheet. Accordingly, the future lease payments of the Extended Ohio Lease are excluded from the table of future minimum lease payments shown above. (17) RELATED PARTY TRANSACTIONS The Company’s corporate offices are leased from an entity in which the Company’s Chief Executive Officer and President (the "CEO"), has an investment interest. This lease expires in October 2028 and contains a five-year extension option. Expenses incurred under this lease were approximately $ 39,000 for each of the three-month periods ended March 31, 2023 and 2022. 29 Table of Contents The Company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the Company’s Chief Operating Officer (the “COO”). Purchases from this entity totaled $ 1.0 million and $ 0.9 million in the three months ended March 31, 2023 and 2022, respectively. The Company pays royalties on the revenue generated from its Betty’s Eddies product line to an entity owned by the COO and its Chief Revenue Officer (the “CRO") under a royalty agreement. This agreement was amended effective January 1, 2021 whereby, among other modifications, the royalty percentage changed from 2.5 % on all sales of Betty’s Eddies products to 3.0 % if sold directly by the Company and between 1.35 % and 2.5 % if licensed by the Company for sale by third parties. Future developed products (i.e., ice cream) have a royalty rate of 0.5 % if sold directly by the Company and between 0.125 % and 0.135 % if licensed by the Company for sale by third parties. The aggregate royalties due to this entity were approximately $ 77,000 and $ 56,000 for the three months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023, one of the Company’s majority-owned subsidiaries paid distributions in the aggregate of approximately $ 1,300 to the CEO, who owns a minority equity interest in such subsidiary. During the three months ended March 31, 2022, this majority-owned subsidiary paid aggregate distributions of approximately $ 11,000 to the Company’s then-CEO and then-Chief Financial Officer (now the CEO), each of whom owned minority equity interests in such subsidiary. During the three months ended March 31, 2023 and 2022, the Company purchased fixed assets and consulting services aggregating $ 267,000 and $ 82,000 , respectively, from two entities owned by two of the Company’s general managers. The Company’s mortgages with Bank of New England, DuQuoin State Bank, and South Porte Bank are personally guaranteed by the CEO. (18) COMMITMENTS AND CONTINGENCIES Maryland Litigation Following the consummation of the Kind Acquisition, in April 2022, litigation between the Company and the members of Kind was dismissed in its entirety with prejudice, and the parties have released one another of any and all claims between them. DiPietro Lawsuit In December 2021, the parties to this action entered into a global confidential settlement and release agreement, along with the parties to the aforementioned Maryland litigation. At the same date, the Company’s wholly-owned subsidiary MariMed Advisors Inc. (“MMA”) and Jennifer DiPietro (“Ms. DiPietro”), one of the former members of Kind, entered into a membership interest purchase agreement pursuant to which the Company would purchase Ms. DiPietro’s interests in Mia Development LLC, the Company's majority-owned subsidiary that owns production and retail cannabis facilities in Wilmington, Delaware, and Mari Holdings MD LLC ("Mari-MD"), the Company's majority-owned subsidiary that owns production and retail cannabis facilities in Hagerstown, Maryland and Annapolis Maryland. Upon the court’s approval of the parties’ joint motion for approval, on June 8, 2022, the purchase of Ms. DiPietro’s interests was consummated. The parties released all direct and derivative claims against one another, and a stipulation dismissing all claims and counterclaims with prejudice was filed with the court. Bankruptcy Claim During 2019, the Company’s MMH subsidiary sold and delivered hemp seed inventory to GenCanna Global Inc., a Kentucky-based cultivator, producer, and distributor of hemp (“GenCanna”). At the time of sale, the Company owned a 33.5 % ownership interest in GenCanna. The Company recorded a related party receivable of approximately $ 29 million from the sale, which was fully reserved at December 31, 2019. On January 24, 2020, an involuntary bankruptcy proceeding under Chapter 11 was filed against GenCanna and its wholly-owned subsidiary, OGGUSA Inc. (f/k/a GenCanna Global US, Inc.) ("OGGUSA" and together with GenCanna, the "OGGUSA Debtors") in the U.S. Bankruptcy Court in the Eastern District of Kentucky (the "Bankruptcy Court"). In February 2020, the OGGUSA Debtors, under pressure from certain of its creditors including its senior lender MGG Investment Group LP ("MGG"), agreed to convert the involuntary bankruptcy proceeding into a voluntary Chapter 11 30 Table of Contents proceeding. The OGGUSA Debtors' subsidiary, Hemp Kentucky LLC, also filed voluntary petitions under Chapter 11 in the Bankruptcy Court. In May 2020, after an abbreviated solicitation/bid/sale process, the Bankruptcy Court, over numerous objections by creditors and shareholders of the OGGUSA Debtors, which included the Company, entered an order authorizing the sale of all or substantially all of the assets of the OGGUSA Debtors to MGG. After the consummation of the sale of all or substantially all of their assets and business, the OGGUSA Debtors filed their liquidating plan of reorganization (the “Liquidating Plan”) to collect various prepetition payments and commercial claims against third parties, liquidate the remaining assets of the OGGUSA Debtors, and make payments to creditors. The Liquidating Plan was confirmed by the Bankruptcy Court on November 12, 2020. Since the approval of the Liquidating Plan, the OGGUSA Debtors have been in the process of liquidating the remaining assets, negotiating and prosecuting objections to other creditors’ claims, and pursuing the collection of accounts receivable and Chapter 5 bankruptcy avoidance claims. In January 2022, the Company, at the request of Oxford Restructuring Advisors LLC, the administrator of the Liquidating Plan for the OGGUSA Debtors (the "Plan Administrator"), executed a written release of claims, if any, of the Company against Huron Consulting Group (“Huron”), a financial consulting and management company retained by the senior lender of the OGGUSA Debtors to perform loan management services for the lender and OGGUSA Debtors prior to and during their Chapter 11 bankruptcy cases. Such release was executed in connection with a comprehensive settlement agreement between the OGGUSA Debtors and Huron. In consideration for the Company’s execution of the release, Huron paid an additional $ 40,000 to the bankruptcy estates of the OGGUSA Debtors to be included in the funds to be distributed to creditors, including the Company. In connection with the discussions of the Company with the OGGUSA Debtors relating to the Huron settlement, the Plan Administrator raised issues relating to a potential claim against MariMed Hemp, Inc. ("MHI") for certain preferential transfers of assets, which were valued at $ 250,000 by the Plan Administrator, of the OGGUSA Debtors alleged to have been made to MHI in payment of a $ 600,000 loan made by the Company prior to the Chapter 11 bankruptcy of the OGGUSA Debtors (the "Preferential Claim"). On April 20, 2022, the Plan Administrator filed its Complaint to Avoid and Recover Transfers Pursuant to 11 U.S.C. §§547 and 550 and to Disallow Claims Pursuant to 11 U.S.C. §502 (the "Complaint"), asserting the Preferential Claim seeking the recovery of an amount no less than $ 200,000 and to disallow the MHI claim until such time as such preferential transfer has been repaid to the OGGUSA Debtors. On August 1, 2022, an answer to the Complaint was filed, asserting counterclaims and third-party claims against OGGUSA, the Plan Administrator, and Huron for declaratory judgment (the "Related Claims") in relation to terms of the Plan of Reorganization (the "Plan") and the allowance of the MHI claim under the Plan. The Company has and continues to vigorously deny that any of the Preferential Claim exists in that such claims were waived and released in connection with the Company's settlement agreement and stipulations for its support of and voting for the Plan. As such, the Company believes that such claims are meritless and have no basis in fact or law. As of the date of this filing, there is insufficient information as to how much of the Company's allowed general unsecured claim, if any, will be paid upon the completion of the liquidation of the remaining assets of the OGGUSA Debtors. (19) SUBSEQUENT EVENTS Equity Transactions Subsequent to March 31, 2023, the following equity transactions occurred: • On April 5, 2023, the Company issued 1,290 restricted common shares under a royalty agreement. • On April 5, 2023, the Company issued 5,025 restricted common shares in satisfaction of shares subscribed at March 31, 2023. • On April 17, 2023, the Company issued 349,999 common shares underlying RSUs that vested on that date. • On April 21, 2023, the Company issued 450,000 restricted common shares to purchase a 0.33 % minority interest in Mari Holdings MD LLC, one of the Company's majority-owned subsidiaries. • On April 25, 2023, the Company received a conversion notice from Hadron in connection with its conversion of 2,651,404 Series C Preferred shares into 13,257,020 common shares. The Company issued the shares and 31 Table of Contents arranged for the delivery of a new stock certificate covering the remaining outstanding 3,564,818 Series C Preferred shares. The effective date of the conversion was April 25, 2023. 32 Table of Contents